Trajectories in New York Heart Association functional class in heart failure across the ejection fraction spectrum: data from the Swedish Heart Failure Registry

To investigate incidence, predictors and prognostic implications of longitudinal New York Heart Association (NYHA) class changes (i.e. improving or worsening vs. stable NYHA class) in heart failure (HF) across the ejection fraction (EF) spectrum.

[1]  L. Lund,et al.  Use of evidence‐based therapy in heart failure with reduced ejection fraction across age strata , 2022, European journal of heart failure.

[2]  L. Lund,et al.  Patient profile and outcomes associated with follow‐up in specialty vs. primary care in heart failure , 2022, ESC heart failure.

[3]  Natasha Meunier-McVey,et al.  2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure , 2021, EMJ Cardiology.

[4]  G. Fonarow,et al.  Comparison of New York Heart Association Class and Patient-Reported Outcomes for Heart Failure With Reduced Ejection Fraction. , 2021, JAMA cardiology.

[5]  J. Daubert,et al.  Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study. , 2021, JACC. Clinical electrophysiology.

[6]  S. Solomon,et al.  Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials , 2020, The Lancet.

[7]  L. Lund,et al.  Comorbidities and cause-specific outcomes in heart failure across the ejection fraction spectrum: A blueprint for clinical trial design. , 2020, International journal of cardiology.

[8]  本田 純久.  Longitudinal Data , 2003, Encyclopedia of Wireless Networks.

[9]  Zi-Xin Zhang,et al.  Quality of life and outcomes in heart failure patients with ejection fractions in different ranges , 2019, PloS one.

[10]  A. Strömberg,et al.  Nurse‐Led Heart Failure Clinics Are Associated With Reduced Mortality but Not Heart Failure Hospitalization , 2019, Journal of the American Heart Association.

[11]  L. Lund,et al.  Prevalence and Prognostic Implications of Longitudinal Ejection Fraction Change in Heart Failure. , 2019, JACC. Heart failure.

[12]  S. Saksena,et al.  Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction , 2019, Journal of Interventional Cardiac Electrophysiology.

[13]  G. Barbati,et al.  HF progression among outpatients with HF in a community setting. , 2019, International journal of cardiology.

[14]  L. Lund,et al.  The Swedish Heart Failure Registry: a living, ongoing quality assurance and research in heart failure , 2018, Upsala journal of medical sciences.

[15]  J. McMurray,et al.  Temporal Trends and Patterns in Mortality After Incident Heart Failure A Longitudinal Analysis of 86 000 Individuals , 2019 .

[16]  Roberto Ferrari,et al.  Epidemiology and one‐year outcomes in patients with chronic heart failure and preserved, mid‐range and reduced ejection fraction: an analysis of the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[17]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[18]  Stef van Buuren,et al.  Flexible Imputation of Missing Data , 2012 .

[19]  Stef van Buuren,et al.  MICE: Multivariate Imputation by Chained Equations in R , 2011 .

[20]  J. Burkhardt,et al.  Cardiac resynchronization therapy in patients with mild heart failure: a systematic review and meta-analysis , 2011, Journal of Interventional Cardiac Electrophysiology.

[21]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[22]  J. Walsh,et al.  Impact of specialist care in patients with newly diagnosed heart failure: a randomised controlled study. , 2007, International journal of cardiology.

[23]  Richard Sutton,et al.  Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure , 2006, Heart.

[24]  W. Abraham,et al.  Clinical predictors and timing of New York Heart Association class improvement with cardiac resynchronization therapy in patients with advanced chronic heart failure: results from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) and Multicenter InSync ICD Randomized Clinical Evaluatio , 2006, American heart journal.

[25]  H. Krumholz,et al.  Monitoring clinical changes in patients with heart failure: a comparison of methods. , 2005, American heart journal.

[26]  M. Packer,et al.  Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. , 2001, Journal of cardiac failure.

[27]  B. Pitt,et al.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. , 1999, The New England journal of medicine.

[28]  J. Hansen,et al.  Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. , 1994, European heart journal.

[29]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.